丹麦二十年间风湿性多肌痛的发病率与病程:跨医疗部门的全国性研究
该研究利用丹麦全国性人群队列,基于新算法跨医疗部门识别2003至2024年间50岁及以上风湿性多肌痛(PMR)患者,共51,401例。年龄标化发病率为112/10万人(95%CI 110.8-112.8),初级医疗发病率下降53%而二级医疗上升30%,总体下降12%。巨细胞动脉炎(GCA)发生率为5.4/1000患者年,多数在PMR诊断后第一年内出现;28%和22%的患者在5年和10年后仍使用泼尼松/泼尼松龙(PDN),中位日剂量分别为4.1 mg和5.5 mg。
要点
- 丹麦PMR年龄标化发病率为112/10万人,总体发病率下降12%。
- GCA发生率为5.4/1000患者年,中位出现时间为PMR诊断后68天。
- 28%和22%的患者在5年和10年后仍用PDN,提示需早期联合治疗。
核心结论
- 二级医疗PMR发病率增加被初级医疗下降所抵消,总体发病率下降12%。
- 多数晚发GCA在PMR诊断后第一年内发生。
- 许多患者持续使用PDN 5至10年,提示需要更早使用伴随治疗。
研究设计与样本
- 丹麦全国性、基于人群的队列研究,采用个体水平数据链接。
- 通过新算法在2003年1月1日至2024年11月1日间识别50岁及以上PMR患者。
主要发现
- 共识别51,401例PMR患者,其中初级医疗24,456例,二级医疗26,945例。
- 年龄标化发病率为112/10万人(95%CI 110.8-112.8)。
- 研究期间初级医疗发病率下降53%,二级医疗上升30%,总体下降12%。
- PMR患者中GCA发生率为5.4/1000患者年(95%CI 5.1-5.7),中位间隔68天(IQR 10-602)。
- 28%和22%的患者在5年和10年后仍接受PDN治疗,中位日剂量分别为4.1 mg和5.5 mg。
临床怎么用
- 临床应关注PMR诊断后第一年内GCA的发生风险。
- 对长期使用PDN的患者,应考虑更早引入伴随治疗以减少激素暴露。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: A new algorithm enables the identification of patients with polymyalgia rheumatica (PMR) across health care sectors in Denmark. We estimated annual incidence rates from 2003 to 2024 and described the disease course, including the occurrence of late-onset giant cell arteritis (GCA) and prednisolone or prednisone (PDN) treatment. METHODS: A Danish nationwide, population-based cohort study was conducted using data linked at the individual level. Cases were identified among people ages 50 years or older between January 1, 2003, and November 1, 2024. RESULTS: A total of 51,401 patients were identified, including 24,456 from primary care and 26,945 from secondary care. The age-standardized incidence of PMR was 112 per 100,000 people (95% confidence interval [CI] 110.8-112.8). During the study period, the incidence declined by 53% in primary health care and increased by 30% in secondary health care, resulting in an overall decline of 12%. Among patients with PMR, GCA occurred at a rate of 5.4 (95% CI 5.1-5.7) per 1,000 patient-years, with a median of 68 days (interquartile range 10-602) from PMR diagnosis. Overall, 28% and 22% of patients were still treated with PDN after 5 and 10 years, with a median daily dose of 4.1 and 5.5 mg of PDN, respectively. CONCLUSION: The increasing incidence of PMR in secondary health care was exceeded by the declining incidence in primary health care. Most late-onset GCA developed within the first year after PMR diagnosis. Many patients continued treatment with PDN for 5 to 10 years, indicating a need for earlier use of concomitant therapies.
引用
- Donskov AO, Hauge EM, De Thurah A, et al. Incidence and Disease Course of Polymyalgia Rheumatica During Two Decades: A Nationwide Study Across Health Care Sectors in Denmark. Arthritis Rheumatol. 2026. PMID: 42742030. doi:10.1002/art.70337
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。